WallStSmart

The Ensign Group Inc (ENSG)vsGuardian Pharmacy Services, Inc. (GRDN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The Ensign Group Inc generates 262% more annual revenue ($5.27B vs $1.46B). ENSG leads profitability with a 6.9% profit margin vs 3.6%. ENSG trades at a lower P/E of 27.9x. ENSG earns a higher WallStSmart Score of 62/100 (C+).

ENSG

Buy

62

out of 100

Grade: C+

Growth: 8.0Profit: 6.0Value: 4.0Quality: 6.0
Piotroski: 4/9Altman Z: 2.15

GRDN

Hold

50

out of 100

Grade: D+

Growth: 7.3Profit: 6.5Value: 4.7Quality: 7.0
Piotroski: 3/9Altman Z: 5.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENSGSignificantly Overvalued (-45.8%)

Margin of Safety

-45.8%

Fair Value

$145.31

Current Price

$178.83

$33.52 premium

UndervaluedFair: $145.31Overvalued

Intrinsic value data unavailable for GRDN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENSG2 strengths · Avg: 8.0/10
Revenue GrowthGrowth
18.4%8/10

18.4% revenue growth

EPS GrowthGrowth
21.9%8/10

Earnings expanding 21.9% YoY

GRDN4 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
5.1810/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
24.0%9/10

Every $100 of equity generates 24 in profit

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
39.0%8/10

Earnings expanding 39.0% YoY

Areas to Watch

ENSG3 concerns · Avg: 3.7/10
PEG RatioValuation
1.514/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Profit MarginProfitability
6.9%3/10

6.9% margin — thin

GRDN4 concerns · Avg: 3.5/10
Price/BookValuation
11.8x4/10

Trading at 11.8x book value

Revenue GrowthGrowth
2.2%4/10

2.2% revenue growth

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth, EPS Growth. Revenue growth of 18.4% demonstrates continued momentum.

Bull Case : GRDN

The strongest argument for GRDN centers on Altman Z-Score, Return on Equity, Debt/Equity.

Bear Case : ENSG

The primary concerns for ENSG are PEG Ratio, P/E Ratio, Profit Margin.

Bear Case : GRDN

The primary concerns for GRDN are Price/Book, Revenue Growth, Profit Margin. A P/E of 48.2x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

ENSG profiles as a growth stock while GRDN is a value play — different risk/reward profiles.

ENSG is growing revenue faster at 18.4% — sustainability is the question.

ENSG generates stronger free cash flow (119M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ENSG scores higher overall (62/100 vs 50/100) and 18.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Guardian Pharmacy Services, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Guardian Pharmacy Services, Inc. is a leading provider of specialized pharmacy solutions focused on the long-term care sector, servicing assisted living and skilled nursing facilities. Known for its commitment to personalized medication management and stringent quality standards, the company leverages advanced technology and deep pharmaceutical expertise to enhance patient outcomes. With an extensive operational presence across multiple states, Guardian is well-positioned to address the growing demand for customized pharmacy services, ensuring optimal operational efficiency for its healthcare partners in an evolving market.

Want to dig deeper into these stocks?